Transcriptomic Determinants of Circulating Immunity Predict Immune‐Related Adverse Events ( <scp>irAEs</scp> ) in Cancer Patients Receiving <scp>PD</scp> ‐1/ <scp>PD</scp> ‐ <scp>L1</scp> Blockade

Together, we revealed crucial circulating immunological determinants in irAEs and provided promising biomarkers to help predict irAEs, which will enlighten future precise management and targeted treatment strategies for irAEs.